William Hilson
Chairman bei Diamond Therapeutics, Inc.
Profil
William Hilson is currently the Executive Chairman at Diamond Therapeutics, Inc., Director at Cronos Growing Co., Inc., and Director at Silvermine Arts Center.
Previously, he worked as the Regional Chief Financial Officer at Merck KGaA and Serono SA. He also served as the Chief Financial Officer at Cronos Group, Inc. from 2016 to 2019.
Hilson received his undergraduate degree from the University of Toronto and his graduate degree from the University of Western Ontario.
Aktive Positionen von William Hilson
Unternehmen | Position | Beginn |
---|---|---|
Cronos Growing Co., Inc.
Cronos Growing Co., Inc. Real Estate DevelopmentFinance Cronos Growing Co., Inc. provides cannabis products. It specializes in cannabis farming, cannabis cultivation and extraction products. The company is headquartered in Toronto, Canada. | Director/Board Member | - |
Diamond Therapeutics, Inc.
Diamond Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Diamond Therapeutics, Inc. is a Canadian clinical-stage drug development company founded in 2018 by Judy Blumstock. The company is based in an undisclosed location and is focused on developing safe, FDA, EMA, and Health Canada approved therapies for neuropsychiatric conditions. The company is developing sub-perceptual, non-hallucinogenic, psychedelic-based treatments that hold potential for use across a broad patient cohort, with the goal of maximizing the positive impact better drugs can have on the mental health crisis. Diamond's mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. | Chairman | - |
Silvermine Arts Center | Director/Board Member | - |
Ehemalige bekannte Positionen von William Hilson
Unternehmen | Position | Ende |
---|---|---|
MERCK KGAA | Corporate Officer/Principal | - |
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | Corporate Officer/Principal | - |
CRONOS GROUP INC. | Director of Finance/CFO | 15.04.2019 |
Ausbildung von William Hilson
University of Toronto | Undergraduate Degree |
University of Western Ontario | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
MERCK KGAA | Health Technology |
CRONOS GROUP INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | Health Technology |
Cronos Growing Co., Inc.
Cronos Growing Co., Inc. Real Estate DevelopmentFinance Cronos Growing Co., Inc. provides cannabis products. It specializes in cannabis farming, cannabis cultivation and extraction products. The company is headquartered in Toronto, Canada. | Finance |
Diamond Therapeutics, Inc.
Diamond Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Diamond Therapeutics, Inc. is a Canadian clinical-stage drug development company founded in 2018 by Judy Blumstock. The company is based in an undisclosed location and is focused on developing safe, FDA, EMA, and Health Canada approved therapies for neuropsychiatric conditions. The company is developing sub-perceptual, non-hallucinogenic, psychedelic-based treatments that hold potential for use across a broad patient cohort, with the goal of maximizing the positive impact better drugs can have on the mental health crisis. Diamond's mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. | Health Technology |
Silvermine Arts Center |